The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD (Advair and Quality of Sleep in COPD).

Trial Profile

The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD (Advair and Quality of Sleep in COPD).

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 29 Feb 2012

At a glance

  • Drugs Salmeterol/fluticasone propionate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics
  • Acronyms AQuOS-COPD
  • Most Recent Events

    • 29 Feb 2012 Actual patient number (0) added as reported by ClinicalTrials.gov.
    • 29 Feb 2012 Planned end date changed from 1 Sep 2010 to 1 Feb 2012 as reported by ClinicalTrials.gov.
    • 27 May 2010 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top